Careray Digital Medical Technology Co. Ltd. Class A

Careray Digital Medical Technology Co. Ltd. Class A

SSSE:688607
31.86
CNY
-1.18
(-3.57%)
-0.35EPS
4.49BMarket Cap
Oct 29Next Earn
Careray Digital Medical Technology Co. Ltd. Class A
SSE:688607
(Shanghai Stock Exchange)

Recent

price

31.86

P/E

ratio

- -

div

yld

0.02%

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
3.3
3.24
3.55
5.15
3.98
2.18
3.02
3.38
3.85
3.74
Revenue per Share
0.36
0.75
0.73
1.14
0.99
-0.06
0.17
0.2
-0.08
-0.32
Basic EPS, GAAP
0.45
0.46
0.26
0.97
0.2
-0.6
-0.24
-0.83
-1.66
- -
Free Cash Flow per Basic Share
0.02
0.01
0.01
0.01
0.35
0.28
- -
0.06
0.07
0.01
Dividend per Share
2.94
3.71
4.44
5.58
9.88
9.58
9.74
9.79
9.69
9.51
Book Value per Share
2.93
3.46
4.24
5.36
9.76
9.5
9.69
9.75
9.63
4.41
Tangible Book Value per Share
60
66
66
66
86
94
91
88
83
87
Basic Weighted Avg Shares
198
213
235
339
342
205
274
298
321
325
Sales/Revenue/Turnover
17.69
24.29
24.37
24.49
23.79
-10.1
2.84
5.79
6.23
-1.46
Operating Margin (%)
3
3
6
6
7
8
10
8
7
- -
Depreciation Expense
22
49
48
75
85
-6
15
18
-7
-28
Net Income, GAAP
19.84
11.81
13.99
14.63
11.66
- -
- -
0.05
- -
- -
Effective Tax Rate (%)
10.9
23.17
20.54
22.15
24.88
-2.75
5.63
5.92
-2.08
-8.67
Profit Margin (%)
181
220
266
338
814
761
717
519
421
278
Working Capital
- -
- -
- -
1
- -
2
2
9
7
248
LT Debt
194
245
294
369
871
844
858
863
853
901
Total Equity
- -
21.12
16.45
21.22
13.17
- -
- -
2.04
- -
- -
Return on Invested Capital (%)
- -
21.41
16.67
21.34
13.44
- -
- -
2.1
- -
- -
Return on Capital (%)
- -
22.44
17.89
22.69
13.73
-0.66
1.81
2.05
-0.78
-3.32
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
36
45
118
LT Borrowings
- -
- -
242
LT Finance Leases
7
7
7
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
88
88
88
Market Capitalization
3,772
5,242
4,495

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
532
517
579
Cash, Cash Equivalents & STI
243
225
270
Accounts Receivable, Net
112
95
100
Inventories
152
152
156
Total Current Liabilities
111
111
301
Payables & Accruals
- -
- -
- -
ST Debt
36
45
118
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
26.83%
-1.05%
Free Cash Flow
- -
-45.39%
88.14%
Net Income, GAAP
- -
-118.07%
-137.77%
Sales/Revenue/Turnover
- -
2.19%
7.63%
Total Cash Common Dividend
- -
4,523.89%
18.63%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
53
76
67
103
298
2025
58
86
- -
95
321
2026
69
75
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.07
0.06
0.06
0.2
2025
-0.04
0.03
- -
-0.08
-0.08
2026
-0.19
-0.09
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.04
0.02
- -
0.06
2025
- -
- -
- -
0.01
0.07
2026
- -
- -
- -
- -
- -
Business
CareRay Digital Medical Technology Co., Ltd. (688607.SS) researches, develops, manufactures, and sells digital X-ray flat panel detectors principally in China with global operations including Europe and North America. The company offers a range of products comprising wireless high-speed dynamic flat panel detectors, wired static radiography panels such as the CareView 1500Cw series, new-generation CMOS and IGZO sensors, specialized panels for breast imaging, fluoroscopy, radiotherapy, interventional surgery, oral three-dimensional imaging, and veterinary applications; it also provides accessories, AI-powered low-dose radiography system solutions, multi-frame imaging upgrades, and OEM custom solutions featuring proprietary technologies like direct-deposit low-dose Cesium iodide (CsI) scintillators, F2AED full-field automatic exposure detection, and 1-Shot Calibration. Founded in 2007 and headquartered in Suzhou, China, CareRay targets medical institutions, diagnostic imaging system developers, and healthcare providers worldwide. In April 2024, the company completed the acquisition of 30% equity in ISDI Limited to strengthen its technological capabilities; it continues to invest in R&D with over a dozen patents and reported revenue fluctuations amid market expansion in 2025.